1Andersson T.Pharmacokinetics,metabolism and interactions of acid pump inhibitors.Focus on omeprazole,lansoprazole and pantoprazole.Clin Pharmacokinet, 1996,31(1):9
2Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol, 1996,8(Suppl.1):S21
3Chang M,Tybring G,Dahl M L,et al.Interphenotype differences in disposition and effect on gastrin levels of omeprazole:Suitability of omeprazole as a probe for CYP2C19.Br J Clin Pharmacol,1995,39(5):511
4Furuta T, Ohashi K,Takashima M,et al. CYP2C19 genotype status and effect of omeprasole on intragastric pH.Gastroenterology, 1998,114:A127
5Furuta T,Ohashik,Kamata T,et al. CYP2C19 genotype status and dual therapy with omeprazole and amoxicillin for eradication of helicobacter pylori and peptic ulcer healing. Gastroenterology, 1998,113:A127
6Flockhart DA.Drug interactions and the cytochrome P450 System.The role of cytochrome P450 2C19.Clin Pharmacokinet, 1995,29(Suppl.1):45
7VandenBranden M,Ring BJ,Binkley SN,et al. Interaction of human liver cytochromes P450 in vitro with LY307640,a gastric proton pump inhibitor. Pharmacogenetics, 1996,6(1):81
8Ko J W,Sukhova N,Thacker D,et al. Evaluation of omeprasole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos, 1997,25(8):853
9Dekkers CPM, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg vs.omeprazole 20 mg in the treatment of active gastric ulcer-a European multicentre study. Aliment Pharmacol Ther,1998,12(1):.789
10Edeki TI,Goldstein JA, Morais SMF,et al. Genetic polymorphism of S-mephenytoin 4i-hydroxylation in African-Americans.Pharma-cogenetics, 1996,6(3):357
10MINER P, PHILIP O, KATZ PO, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole : a five-way crossover study [ J ]. Am J Gastroenterol,2003,98 (12) :2616 - 2620.
